Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 108Stomach Neoplasms 68Pancreatic Neoplasms 33Neoplasms 24Lymphoma, Large B-Cell, Diffuse 22Carcinoma, Non-Small-Cell Lung 21Neoplasm Metastasis 18Rectal Neoplasms 17Colonic Neoplasms 17Esophageal Neoplasms 16Parkinson Disease 4, Autosomal Dominant Lewy Body 13Adenocarcinoma 13Carcinoma, Hepatocellular 12Ovarian Neoplasms 10Biliary Tract Neoplasms 9Adenocarcinoma Of Esophagus 9Esophageal Squamous Cell Carcinoma 8Cholangiocarcinoma 8Gastrointestinal Neoplasms 7Lymphoma, Non-Hodgkin 6Endometrial Neoplasms 6Gallbladder Neoplasms 5Advanced Solid Tumors 5Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Recurrence 4Carcinoma, Pancreatic Ductal 4Breast Neoplasms 4Advanced Solid Tumor 4Solid Tumors 3

Interventions

Ipilimumab 9pembrolizumab 6Nivolumab 4tremelimumab 3Paclitaxel 3Carboplatin 3spartalizumab 2lenvatinib 2durvalumab 2Doxorubicin 2Bevacizumab 2trastuzumab deruxtecan 1tilsotolimod 1tebentafusp 1osimertinib 1eribulin 1envafolimab 1cemiplimab 1balstilimab 1Vemurafenib 1Vascular Endothelial Growth Factor A 1Standard of Care 1Pemetrexed 1Oxaliplatin 1Docetaxel 1Cisplatin 1Capecitabine 1Axitinib 1Antibodies, Bispecific 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Diabetes Mellitus, Insulin-Dependent, 12 × Oxaliplatin × Clear all
NCT03852251 2024-08-02

A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ Adenocarcinoma

Akeso

Phase 1/2 Completed
338 enrolled

Diabetes Mellitus, Insulin-Dependent, 12

Data powered by HemOnc (CC BY 4.0) Colophon âš¡